13.73

0.07% -0.010

After Hours: 13.68 -0.05 -0.36%

Teladoc Health Inc (TDOC)

Overview News Price History Option Chain Discussions Forecast

Teladoc Health Inc stock is currently priced at $13.73, with a 24-hour trading volume of 7.64M. It has seen a -0.07% decreased in the last 24 hours and a -8.47% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $13.70 pivot point. If it approaches the $14.09 resistance level, significant changes may occur.

Previous Close:

$13.74

Open:

$13.73

24h Volume:

7.64M

Market Cap:

$2.27B

Revenue:

$2.60B

Net Income/Loss:

$-220.37M

P/E Ratio:

-0.5568

EPS:

-24.66

Net Cash Flow:

$193.67M

1W Performance:

+4.49%

1M Performance:

-8.47%

6M Performance:

-24.23%

1Y Performance:

-51.26%

1D Range:

$13.41

$14.02

52W Range:

$12.86

$30.41

Teladoc Health Inc Stock (TDOC) Company Profile

Name

Teladoc Health Inc

Sector

Healthcare (1200)

Industry

Health Information Services (61)

Phone

203-635-2002

Address

2 Manhattanville Road, Suite 203, Purchase, NY

Employee

2,032

Twitter

@teladoc

Next Earnings Date

2024-04-25

Latest SEC Filings

TDOC's Discussions on Twitter

Teladoc Health Inc Stock (TDOC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-17-24	Downgrade	DA Davidson	Buy → Neutral
Jan-03-24	Initiated	Barclays	Overweight
Apr-12-23	Initiated	Stephens	Equal-Weight
Feb-23-23	Upgrade	SVB Securities	Market Perform → Outperform
Oct-24-22	Upgrade	Guggenheim	Sell → Neutral
Sep-16-22	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-07-22	Initiated	Truist	Hold
Aug-17-22	Downgrade	Guggenheim	Neutral → Sell
Aug-12-22	Initiated	DA Davidson	Buy
Aug-02-22	Downgrade	Berenberg	Buy → Hold
Aug-02-22	Downgrade	Cowen	Outperform → Market Perform
Jul-28-22	Downgrade	Goldman	Buy → Neutral
Jul-28-22	Downgrade	Needham	Buy → Hold
Jul-06-22	Reiterated	BofA Securities	Neutral
May-05-22	Downgrade	Argus	Buy → Hold
Apr-28-22	Downgrade	Citigroup	Buy → Neutral
Apr-28-22	Downgrade	Credit Suisse	Outperform → Neutral
Apr-28-22	Downgrade	Guggenheim	Buy → Neutral
Apr-28-22	Downgrade	JP Morgan	Overweight → Neutral
Apr-28-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Apr-28-22	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-28-22	Downgrade	William Blair	Outperform → Mkt Perform
Apr-07-22	Initiated	Guggenheim	Buy
Apr-01-22	Resumed	Credit Suisse	Outperform
Mar-03-22	Upgrade	Argus	Hold → Buy
Feb-23-22	Reiterated	BofA Securities	Neutral
Feb-23-22	Reiterated	Craig Hallum	Hold
Feb-23-22	Reiterated	Evercore ISI	In-line
Feb-23-22	Reiterated	Goldman	Buy
Feb-23-22	Reiterated	JP Morgan	Overweight
Feb-23-22	Reiterated	KeyBanc Capital Markets	Overweight
Feb-23-22	Reiterated	Needham	Buy
Feb-23-22	Reiterated	Oppenheimer	Outperform
Feb-23-22	Reiterated	Stifel	Hold
Feb-11-22	Initiated	Goldman	Buy
Feb-08-22	Reiterated	Piper Sandler	Overweight
Dec-02-21	Resumed	Jefferies	Hold
Nov-22-21	Downgrade	BTIG Research	Buy → Neutral
Oct-28-21	Reiterated	Barclays	Equal Weight
Oct-28-21	Reiterated	BofA Securities	Neutral
Oct-28-21	Reiterated	Canaccord Genuity	Buy
Oct-28-21	Reiterated	Citigroup	Buy
Oct-28-21	Reiterated	Craig Hallum	Hold
Oct-28-21	Reiterated	Needham	Buy
Oct-28-21	Reiterated	Oppenheimer	Outperform
Oct-28-21	Reiterated	Piper Sandler	Overweight
Oct-28-21	Reiterated	UBS	Neutral
Oct-19-21	Initiated	Wells Fargo	Overweight
Aug-02-21	Downgrade	Argus	Buy → Hold
Jul-28-21	Downgrade	Deutsche Bank	Buy → Hold
May-28-21	Initiated	Robert W. Baird	Neutral
Apr-15-21	Initiated	Needham	Buy
Jan-07-21	Initiated	BTIG Research	Buy
Dec-22-20	Initiated	Evercore ISI	In-line
Dec-07-20	Downgrade	Stephens	Overweight → Equal-Weight
Dec-04-20	Initiated	Goldman	Neutral
Nov-13-20	Upgrade	Robert W. Baird	Neutral → Outperform
Sep-22-20	Initiated	DA Davidson	Buy
Sep-02-20	Upgrade	Berenberg	Hold → Buy
Aug-17-20	Upgrade	Credit Suisse	Neutral → Outperform
Jul-14-20	Initiated	Citigroup	Buy
Jul-13-20	Initiated	Argus	Buy
Jul-07-20	Initiated	Stephens	Overweight
Apr-30-20	Reiterated	KeyBanc Capital Markets	Overweight
Apr-13-20	Initiated	SVB Leerink	Outperform
Mar-31-20	Downgrade	Berenberg	Buy → Hold
Mar-25-20	Downgrade	Craig Hallum	Buy → Hold
Mar-16-20	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Mar-12-20	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-28-20	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Feb-12-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-10-20	Initiated	UBS	Neutral
Jan-09-20	Downgrade	BofA/Merrill	Buy → Neutral

View All

Teladoc Health Inc Stock (TDOC) Latest News

Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?

Zacks Investment Research

Why Investors Should Choose the Nasdaq-100 Over the Ark Innovation ETF

The Motley Fool

Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week

Benzinga

Should You Buy This Beaten-Down Stock?

The Motley Fool

Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update

Seeking Alpha

Analysts Estimate Teladoc (TDOC) to Report a Decline in Earnings: What to Look Out for

Zacks Investment Research

Teladoc Health Inc Stock (TDOC) Financials Data

Teladoc Health Inc (TDOC) Revenue 2024

TDOC reported a revenue (TTM) of $2.60 billion for the quarter ending December 31, 2023, a +8.13% rise year-over-year.

Teladoc Health Inc (TDOC) Net Income 2024

TDOC net income (TTM) was -$220.37 million for the quarter ending December 31, 2023, a +98.39% increase year-over-year.

Teladoc Health Inc (TDOC) Cash Flow 2024

TDOC recorded a free cash flow (TTM) of $193.67 million for the quarter ending December 31, 2023, a +1,072% increase year-over-year.

Teladoc Health Inc (TDOC) Earnings per Share 2024

TDOC earnings per share (TTM) was -$1.34 for the quarter ending December 31, 2023, a +98.42% growth year-over-year.

Teladoc Health Inc Stock (TDOC) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Trencher Daniel	CHIEF STRATEGY OFFICER	Apr 17 '24	Sale	13.21	1,000	13,210	26,192
Nanis Nikolaos P.	Chief Technology Officer	Apr 02 '24	Sale	14.31	461	6,599	70,621
Geshuri Arnnon	CHIEF PEOPLE OFFICER	Mar 25 '24	Option Exercise	2.73	7,500	20,475	45,970
Geshuri Arnnon	CHIEF PEOPLE OFFICER	Mar 25 '24	Sale	15.06	7,500	112,950	38,470
Trencher Daniel	CHIEF STRATEGY OFFICER	Mar 18 '24	Sale	15.18	1,000	15,180	27,192
Turitz Andrew	EVP, CORPORATE DEVELOPMENT	Mar 05 '24	Sale	14.53	5,647	82,051	33,782
GOREVIC JASON N	CHIEF EXECUTIVE OFFICER	Mar 04 '24	Sale	14.52	53,755	780,308	653,073
Murthy Mala	CHIEF FINANCIAL OFFICER	Mar 04 '24	Sale	14.52	29,888	433,854	71,716
Kornwasser Laizer	PRESIDENT, ENTERPRISE GROWTH	Mar 04 '24	Sale	14.52	18,349	266,354	76,283
Vandervoort Adam C	CHIEF LEGAL OFFICER, SECRETARY	Mar 04 '24	Sale	14.52	15,653	227,219	37,476

Teladoc Health, Inc. provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone. It serves employers of Fortune 1000 companies, health plans, health systems, and other entities. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was founded in 2002 and is headquartered in Purchase, New York.